JCR Pharmaceuticals Co., Ltd.
JCRRF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $33,072,000 | $42,871,000 | $34,343,000 | $51,082,000 |
| % Growth | -22.9% | 24.8% | -32.8% | – |
| Cost of Goods Sold | $11,333,000 | $11,620,000 | $8,886,000 | $10,461,000 |
| Gross Profit | $21,738,000 | $31,251,000 | $25,457,000 | $40,621,000 |
| % Margin | 65.7% | 72.9% | 74.1% | 79.5% |
| R&D Expenses | $0 | $11,234,000 | $8,802,000 | $7,175,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $12,486,000 | $11,678,000 | $13,511,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $28,389,000 | $1,000 | $58,000 | $38,000 |
| Operating Expenses | $28,389,000 | $23,720,000 | $20,480,000 | $20,686,000 |
| Operating Income | -$6,650,000 | $7,532,000 | $4,975,000 | $19,933,000 |
| % Margin | -20.1% | 17.6% | 14.5% | 39% |
| Other Income/Exp. Net | $236,000 | -$288,000 | $437,000 | -$529,000 |
| Pre-Tax Income | -$6,414,000 | $7,244,000 | $5,412,000 | $19,404,000 |
| Tax Expense | -$1,718,000 | $1,707,000 | $1,625,000 | $4,886,000 |
| Net Income | -$4,759,000 | $5,507,000 | $3,772,000 | $14,507,000 |
| % Margin | -14.4% | 12.8% | 11% | 28.4% |
| EPS | -38.43 | 44.13 | 30.34 | 117.26 |
| % Growth | -187.1% | 45.5% | -74.1% | – |
| EPS Diluted | -38.43 | 43.92 | 30.22 | 116.79 |
| Weighted Avg Shares Out | 123,836 | 124,790 | 124,308 | 123,720 |
| Weighted Avg Shares Out Dil | 123,836 | 125,397 | 124,838 | 124,209 |
| Supplemental Information | – | – | – | – |
| Interest Income | $113,000 | $111,000 | $33,000 | $7,000 |
| Interest Expense | $155,000 | $86,000 | $44,000 | $45,000 |
| Depreciation & Amortization | $3,374,000 | $3,197,000 | $1,997,000 | $1,945,000 |
| EBITDA | -$2,885,000 | $10,528,000 | $7,453,000 | $21,394,000 |
| % Margin | -8.7% | 24.6% | 21.7% | 41.9% |